Evidence map›Paper›PMID 37646243›Full record

ReviewTherapeutic advances in respiratory disease

Symptom

Manuela Latorre, Riccardo Pistelli, Giovanna Elisiana Carpagnano, Alessandro Celi, Ilaria Puxeddu, Nicola Scichilone, Antonio Spanevello, Giorgio Walter Canonica, Pierluigi Paggiaro

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in respiratory disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Manuela LatorreNuovo Ospedale Apuano, Massa, Italy.
Riccardo PistelliCatholic University of Roma, Roma, Italy.
Giovanna Elisiana CarpagnanoSection of Respiratory Diseases, Department of Basic Medical Science, Neuroscience and Sense Organs, 'Aldo Moro' University of Bari, Bari, Italy.
Alessandro CeliDepartment of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa, Italy.
Ilaria PuxedduDepartment of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Nicola ScichiloneDepartment of PROMISE, AOUP Giaccone, University of Palermo, Palermo, Italy.
Antonio SpanevelloDepartment of Medicine and Surgery, Pulmonary Diseases Unit, Insubria University, Varese, Italy.
Giorgio Walter CanonicaPersonalized Medicine Asthma and Allergy Clinic, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano, Italy.ORCID 0000-0001-8467-2557
Pierluigi PaggiaroDepartment of Surgery, Medicine, Molecular Biology and Critical Care, University of Pisa, Pisa 5124, Italy.ORCID 0000-0002-1213-2989
University of Pisa · ITHumanitas University · ITOspedale di Prato Santo Stefano · ITUniversità Cattolica del Sacro Cuore · ITUniversity of Bari Aldo Moro · ITUniversity of Insubria · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article traces the concept of asthma control within GINA guidelines over the past 25 years. In the first 15 years after 1995, the main objective of asthma management was to obtain the control of all clinical and functional characteristics of asthma. A landmark study (GOAL) showed for the first time that a good control of asthma is a reasonable outcome that can be achieved in a large proportion of asthmatics with a regular appropriate treatment. In the following years, more emphasis was placed on the role of exacerbations as critical manifestations of poor asthma control, whose frequency is associated with excessive FEV1 decline and increased risk of death. Accordingly, the 2014 GINA report makes a clear distinction between the control of the day-by-day symptoms and the reduction in the risk of severe exacerbations, stating that both conditions should be obtained. The 2019 update included a significant change in the management of mild asthma, prioritizing the prevention of exacerbations to that of mild symptoms. This view was repeated in the 2021 update, where the prevention of exacerbations, together with an acceptable symptom control with a minimal use of rescue medication, appeared to be the real main goal of asthma management. While a discrepancy between current symptoms and exacerbations may be present in mild asthma, a significant relationship between these two features is observed in moderate-severe asthma: a persistent poor symptom control is a major risk factor for exacerbations, whereas achieving symptom control through regular treatment is associated with a reduction in exacerbation rate. Thus, the opinion that frequent symptoms are not important in the absence of acute exacerbations should be discouraged, whereas education of patients to a good symptom perception and to improve adherence to regular treatment should be implemented. Furthermore, the persistence of risk factors, such as increased airway inflammation, even in a patient with minor daily symptoms, should be considered for optimizing treatment.

Indexed as

Anti-Asthmatic AgentsAsthmaAdrenal Cortex HormonesHumansRisk FactorsAdrenal Cortex HormonesAnti-Asthmatic Agentsasthma controlasthma exacerbationGINA guidelinesregular pharmacologic treatmentrescue medication use

Identifiers

PMID37646243
PMCPMC10469243
OpenAlexW4386271249

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.